Question · asked by 1 review
Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin: Survival
- Population
- adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
- Intervention
- Summary of findings: inhaled TOBI® (IV preparation)
- Comparison
- tobramycin
- Outcome
- Survival
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin Survival · adults and children with CF and P aeruginosa The review found no eligible studies for this question. Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.